Dr. Hal Dvorak discusses his early career transition from cellular immunology to cancer biology, and how his group made the discovery of vascular permeability factor (VPF) protein, also known as VEGF-A. Hal discusses specific angiogenic effects VPF/VEGF has on vascular endothelial cells and explains why targeting this pathway in cancer has not proven as beneficial as initially anticipated.